This roundtable series considers the use of combination treatments in patients with relapsed/refractory multiple myeloma who have received 2 or more lines of therapy, as discussed by key opinion leaders and participants at virtual live events.
Reactions to Updated Isatuximab Data in Second-Line Multiple Myeloma
April 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their views on the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with multiple myeloma.
Isatuximab Combo Provides Durable Option in High-Risk Multiple Myeloma
November 20th 2023In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.
Isatuximab Provides Longer Survival in Early Relpase Multiple Myeloma
December 11th 2023In the second article of a 2-part series, Joshua Richter, MD, discusses how the isatuximab, carfilzomib, and dexamethasone regimen fits into the landscape of treatment for patients with early relapsed multiple myeloma.
Isatuximab-Based Triplet Therapy Improves Outcomes in R/R Multiple Myeloma
January 4th 2024In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Isa-Kd Stands Out Among Subsequent Regimens in Multiple Myeloma
April 4th 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.